Among the 14 patients with HER2 overexpression, 9 received adjuvant trastuzumab, while the remaining 5 did not, as trastuzumab had not yet been approved for the treatment of HER2-positive early BC at that time. The gene discussed is ERBB2; the disease is breast cancer.